- Home
- AVIR vs AVR Comparison
AVIR vs AVR Comparison
Compare AVIR & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- AVR
- Stock Information
- Founded
- AVIR 2012
- AVR 1999
- Country
- AVIR United States
- AVR Australia
- Employees
- AVIR N/A
- AVR N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- AVR
- Sector
- AVIR Health Care
- AVR
- Exchange
- AVIR Nasdaq
- AVR NYSE
- Market Cap
- AVIR 273.7M
- AVR 241.5M
- IPO Year
- AVIR 2020
- AVR 2024
- Fundamental
- Price
- AVIR $2.55
- AVR $4.10
- Analyst Decision
- AVIR Hold
- AVR Strong Buy
- Analyst Count
- AVIR 1
- AVR 4
- Target Price
- AVIR $6.00
- AVR $16.50
- AVG Volume (30 Days)
- AVIR 532.5K
- AVR 210.3K
- Earning Date
- AVIR 05-12-2025
- AVR 05-13-2025
- Dividend Yield
- AVIR N/A
- AVR N/A
- EPS Growth
- AVIR N/A
- AVR N/A
- EPS
- AVIR N/A
- AVR N/A
- Revenue
- AVIR N/A
- AVR $2,493,000.00
- Revenue This Year
- AVIR N/A
- AVR $29.52
- Revenue Next Year
- AVIR N/A
- AVR $204.83
- P/E Ratio
- AVIR N/A
- AVR N/A
- Revenue Growth
- AVIR N/A
- AVR N/A
- 52 Week Low
- AVIR $2.60
- AVR $2.34
- 52 Week High
- AVIR $4.15
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- AVIR 37.12
- AVR N/A
- Support Level
- AVIR $2.66
- AVR N/A
- Resistance Level
- AVIR $3.01
- AVR N/A
- Average True Range (ATR)
- AVIR 0.15
- AVR 0.00
- MACD
- AVIR -0.03
- AVR 0.00
- Stochastic Oscillator
- AVIR 7.02
- AVR 0.00
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.